Full Text
EE306 Cost-Utility Analysis of Ocrelizumab for Treating Relapsing Multiple Sclerosis in Austria

Abstract

Authors

Evelyn Walter Christoph Goger Veronika Mikl

Back to Volume 28, Supplemental Issue 12S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×